Feature | December 09, 2013

ACC Helps Hospitals, Patients Avoid Readmissions

Navigator program brings team approach to meeting patient needs, reducing rehospitalization

December 9, 2013 — With increased penalties in effect for hospitals with excessive readmissions for heart attack and heart failure, the American College of Cardiology (ACC) is launching a program that applies a team approach to keeping patients at home and healthy after discharge.
 
The ACC created the Patient Navigator Program to support a team of caregivers at selected hospitals to help patients overcome challenges during their hospital stay and in the weeks following discharge when they are at most risk for readmission. Hospitals have been given funding to establish a program that supports a culture of patient-centered care that can potentially be implemented in other hospitals in the future. AstraZeneca is the founding sponsor of the ACC Patient Navigator Program.
 
“The ACC Patient Navigator Program will serve as a test for innovative, patient-centered solutions to address issues that impact patient health and patient readmissions,” said John Harold, M.D., MACC, and president, ACC. “These hospitals will serve as pioneers in a new approach to heart disease treatment and care that puts emphasis on meeting patients’ ongoing needs and helping patients make a seamless transition from the hospital to the home.”
 
The Centers for Medicare and Medicaid Services increased penalties beginning Oct. 1 for hospitals with excessive readmission rates for heart attack, heart failure and three other non-cardiac conditions within 30 days of discharge. Hospitals could lose up to 2 percent of related Medicare and Medicaid reimbursements, which is double the prior maximum penalty of 1 percent of Medicare payments. Beginning in 2014, the penalty will increase again to a maximum of 3 percent.
 
Nearly one in five patients hospitalized with heart attack and one in four patients hospitalized with heart failure are readmitted within 30 days of discharge, often for conditions seemingly unrelated to the original diagnosis. Readmissions can be related to issues like stresses while in the hospital, fragility on discharge, lack of understanding of discharge instructions and inability to carry out discharge instructions.
 
Out of 132 hospitals initially surveyed about the program, 120 expressed an interest in participating in the first phase of the ACC Patient Navigator Program. Eleven hospitals were chosen for a 2013 program launch, with an additional 24 hospitals slated to join the program by the end of 2015.
 
Listed below are the first 11 participating hospitals, which were chosen because of their commitment to quality demonstrated by participation in the National Cardiovascular Data Registry and Hospital to Home program:
  • Advocate Sherman Hospital, Elgin, Ill.
  • Christiana Care Health Services, Wilmington, Del.
  • Einstein Medical Center Philadelphia, Philadelphia
  • Indiana University Health Methodist Hospital, Indianapolis
  • MedStar Washington Hospital Center, Washington
  • Providence St. Vincent Medical Center, Portland, Ore.
  • Ronald Reagan UCLA Medical Center, Los Angeles
  • St. Mary’s Hospital, Waterbury, Conn.
  • Trident Health, Charleston, S.C.
  • Vanderbilt Heart and Vascular Institute, Nashville, Tenn.
  • WakeMed Health and Hospital, Raleigh, N.C.
 
For more information: www.cardiosource.org

Related Content

FFR-CT, HeartFlow, PLATFORM trial, ESC 2015, ICA, fractional flow reserve, computed tomography

Image courtesy of HeartFlow Inc.

Feature | FFR Catheters| September 03, 2015
Results of the PLATFORM trial indicate fractional flow reserve computed tomography (FFR-CT) can obviate the need for...
News | Structural Heart| September 02, 2015
An investigational material known as Bioabsorbable Cardiac Matrix (BCM), designed to prevent cardiac remodeling in...
Valtech, cardioband, transcatheter mitral annuloplasty

Valtech's Cardioband transcatheter mitral annuloplasty system in development. It is uses a series of corkscrew anchors, similar to those used on EP implantable device leads, to install the annuloplasty ring to reshape the valve for improved leaflet coaptation.

Feature | Structural Heart| September 02, 2015
September 2, 2015 — HeartWare International Inc.
acute ischemic stroke, larger thrombi retrieval, improved neurological recovery, ESC 2015, MR CLEAN trial, sub-study
Feature | Thrombectomy Devices| September 02, 2015
Retrieval of larger thrombi during intra-arterial treatment (IAT) is associated with improved neurological recovery...
DOPPLER-CIP trial, ESC 2015, heart failure, predictor, small left ventricle, University of Leuven
Feature | Heart Failure| September 02, 2015
Findings presented at the European Society of Cardiology (ESC) Congress 2015 indicate that a small left ventricle with...
chest pain, triage, emergency department, new rapid assay, Dirk Westermann, BACC study, ESC 2015
News | Blood Testing| September 02, 2015
Emergency department patients with chest pain suggestive of acute myocardial infarction (AMI) can be triaged more...
Medtronic, OPTILINK, OptiVol, ICD, pulmonary congestion, ESC 2015
Feature | Heart Failure| September 01, 2015
Automated alerts for excess fluid accumulation in the lungs did not improve outcomes for heart failure patients with...
Pie Medical Imaging, Frost & Sullivan, technology leadership, CAAS, cardiovascular diagnostics

CAAS MRV is part of Pie Medical Imaging's suite of imaging solutions for quantitative cardiovascular diagnosis and treatment planning. - See more at: http://www.itnonline.com/content/pie-medical-imaging-recognized-innovati...

News | Cardiac Imaging| September 01, 2015
Based on its recent analysis of the cardiovascular image management market, Frost & Sullivan recognizes Pie Medical...
Absorb, BVS, bioresorbable stent
News | Stents Bioresorbable| September 01, 2015
September 1, 2015 — A bioresorbable drug-eluting coronary stent showed similar efficacy and safety results compared t
bivalirudin,angiomax
Feature | Antiplatelet and Anticoagulation Therapies| September 01, 2015
September 1, 2015 — Extending treatment with the anticoagulant bivalirudin for at least four hours after completion o
Overlay Init